These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 30405515)
1. Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onset Pompe Disease (LOPD). Parisi D; Musumeci O; Mondello S; Brizzi T; Oteri R; Migliorato A; Ciranni A; Mongini TE; Rodolico C; Vita G; Toscano A Front Neurol; 2018; 9():880. PubMed ID: 30405515 [No Abstract] [Full Text] [Related]
2. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy. Pascarella A; Terracciano C; Farina O; Lombardi L; Esposito T; Napolitano F; Franzese G; Panella G; Tuccillo F; la Marca G; Bernardini S; Boffo S; Giordano A; Di Iorio G; Melone MAB; Sampaolo S J Cell Physiol; 2018 Aug; 233(8):5829-5837. PubMed ID: 29215735 [TBL] [Abstract][Full Text] [Related]
3. PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease. Hagemans ML; Stigter RL; van Capelle CI; van der Beek NA; Winkel LP; van Vliet L; Hop WC; Reuser AJ; Beishuizen A; van der Ploeg AT J Inherit Metab Dis; 2010 Apr; 33(2):133-9. PubMed ID: 20107902 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic tools in late onset Pompe disease (LOPD). Musumeci O; Toscano A Ann Transl Med; 2019 Jul; 7(13):286. PubMed ID: 31392198 [TBL] [Abstract][Full Text] [Related]
5. White matter lesions in treated late onset Pompe disease are not different to matched controls. Schneider I; Hensel O; Zierz S Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821 [TBL] [Abstract][Full Text] [Related]
6. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy. Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398 [TBL] [Abstract][Full Text] [Related]
7. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant. Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071 [TBL] [Abstract][Full Text] [Related]
8. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277 [TBL] [Abstract][Full Text] [Related]
9. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale. Hundsberger T; Schoser B; Leupold D; Rösler KM; Putora PM J Neurol; 2019 Aug; 266(8):2010-2017. PubMed ID: 31104135 [TBL] [Abstract][Full Text] [Related]
10. BNIP3 Is Involved in Muscle Fiber Atrophy in Late-Onset Pompe Disease Patients. Carrasco-Rozas A; Fernández-Simón E; Suárez-Calvet X; Piñol-Jurado P; Alonso-Pérez J; de Luna N; Schoser B; Meinke P; Domínguez-González C; Hernández-Laín A; Paradas C; Rivas E; Illa I; Olivé M; Gallardo E; Díaz-Manera J Am J Pathol; 2022 Aug; 192(8):1151-1166. PubMed ID: 35605642 [TBL] [Abstract][Full Text] [Related]
11. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients. Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F; Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025 [TBL] [Abstract][Full Text] [Related]
12. Decreased outlet angle of the superior cerebellar artery as indicator for dolichoectasia in late onset Pompe disease. Hensel O; Schneider I; Wieprecht M; Kraya T; Zierz S Orphanet J Rare Dis; 2018 Apr; 13(1):57. PubMed ID: 29653542 [TBL] [Abstract][Full Text] [Related]
13. Selective screening of late-onset Pompe disease (LOPD) in patients with non-diagnostic muscle biopsies. Meznaric M; Fumic K; Leonardis L J Clin Pathol; 2019 Jul; 72(7):468-472. PubMed ID: 30878973 [TBL] [Abstract][Full Text] [Related]
14. Quantitative whole-body magnetic resonance imaging in children with Pompe disease: Clinical tools to evaluate severity of muscle disease. Fernandes SA; Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS JIMD Rep; 2021 Jan; 57(1):94-101. PubMed ID: 33473345 [TBL] [Abstract][Full Text] [Related]
15. Pompe disease in Austria: clinical, genetic and epidemiological aspects. Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627 [TBL] [Abstract][Full Text] [Related]
16. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group. Filosto M; Cotti Piccinelli S; Ravaglia S; Servidei S; Moggio M; Musumeci O; Donati MA; Pegoraro E; Di Muzio A; Maggi L; Tonin P; Marrosu G; Sancricca C; Lerario A; Sacchini M; Semplicini C; Bozzoni V; Telese R; Bonanno S; Piras R; Maioli MA; Ricci G; Vercelli L; Galvagni A; Gallo Cassarino S; Caria F; Mongini T; Siciliano G; Padovani A; Toscano A Adv Ther; 2019 May; 36(5):1177-1189. PubMed ID: 30879255 [TBL] [Abstract][Full Text] [Related]
17. Cell Ratio Differences in Peripheral Blood between Early- and Late-Onset Parkinson's Disease: A Case-Control Study. Jiang S; Wang Y; Gao H; Luo Q; Wang D; Li Y; Yong Y; Yang X Biomed Res Int; 2019; 2019():2072635. PubMed ID: 31781596 [TBL] [Abstract][Full Text] [Related]
18. Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study. Confalonieri M; Vitacca M; Scala R; Polverino M; Sabato E; Crescimanno G; Ceriana P; Antonaglia C; Siciliano G; Ring N; Zacchigna S; Salton F; Vianello A; Orphanet J Rare Dis; 2019 Mar; 14(1):62. PubMed ID: 30832705 [TBL] [Abstract][Full Text] [Related]
19. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618 [TBL] [Abstract][Full Text] [Related]
20. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry. Scheidegger O; Leupold D; Sauter R; Findling O; Rösler KM; Hundsberger T J Neurol; 2018 Dec; 265(12):2783-2788. PubMed ID: 30232608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]